Results 101 to 110 of about 3,686,577 (308)

The spatial distribution of radiodense breast tissue: a longitudinal study. [PDF]

, 2009
INTRODUCTION: Mammographic breast density is one of the strongest known markers of susceptibility to breast cancer. To date research into density has relied on a single measure (for example, percent density (PD)) summarising the average level of density ...
Pinto Pereira, Snehal M, McCormack, Valerie A, Isabel dos Santos Silva, Sue M Moss, Moss, Sue M, dos Santos Silva, Isabel, Valerie A McCormack, Snehal M Pinto Pereira   +7 more
core   +2 more sources

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Investigating the relationship between mammographic breast density and triple negative breast cancer in Nova Scotia, Canada

, 2020
The study objectives were to estimate the association between mammographic breast density (MBD) and triple negative breast cancers (TNBC); as well as to estimate the discriminatory ability of MBD, alone and with clinical risk factors, in the screening ...
Paquet, Nicole
core  

Dense breast as a risk factor in breast malignancy

مجلة كلية الطب, 2015
Background: One of the strongest risk factors for breast cancer is high breast density, relatively little fat in the breast and more connective and glandular tissue. Objectives: this study aims to measure risk of increase breast density in correlation of
Saabh Ismail Khalil, Enam A. Khalel, Tharwat I. Sulaiman   +2 more
doaj   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Breast Density and Breast Cancer [PDF]

Journal of the Advanced Practitioner in Oncology, 2020
openaire   +2 more sources

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Breast compression parameters and mammographic density in the Norwegian Breast Cancer Screening Programme

, 2017
Objectives To investigate possible associations between breast compression parameters, including compression force, pressure and compressed breast thickness, and mammographic density assessed by an automated software.
Moshina, Nataliia, Roman, Marta, Ursin, Giske, Sebuødegård, Sofie, Waade, Gunvor G., Hofvind, Solveig   +5 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source